HAYWARD, Calif., March 3, 2022 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company, today announced that it will release fourth quarter
financial results after market close on Thursday, March 10, 2022. AcelRx management will
host a live webcast and conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 10, 2022 to discuss the financial results
and provide an update on the company's business.
The webcast is accessible by visiting the Investors page of the
company's website at www.acelrx.com and clicking on the
webcast link on the Investors home page. The webcast will be
accompanied by a slide presentation. A webcast replay will be
available on the AcelRx website for 90 days following the call by
visiting the Investor page of the company's website at
www.acelrx.com.
Investors who wish to participate in the conference call may do
so by dialing (866) 361-2335 for domestic callers, (855) 669-9657
for Canadian callers, or (412) 902-4204 for international
callers.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's proprietary,
non-invasive sublingual formulation technology delivers sufentanil
with consistent pharmacokinetic profiles. The Company has one
approved product in the U.S., DSUVIA® (sufentanil sublingual
tablet, 30 mcg), known as DZUVEO® in Europe, indicated for the management of acute
pain severe enough to require an opioid analgesic for adult
patients in certified medically supervised healthcare settings, and
several product candidates. The product candidates include:
Zalviso® (sufentanil sublingual tablet system, SST system, 15 mcg),
an investigational product in the U.S. being developed as an
innovatively designed patient-controlled analgesia (PCA) system for
reduction of moderate-to-severe acute pain in medically supervised
settings; two pre-filled, ready-to-use syringes of ephedrine and
phenylephrine licensed for the U.S. from Aguettant; Niyad™, a
regional anticoagulant for the extracorporeal circuit; and LTX-608,
for the potential treatment of COVID-19, disseminated intravascular
coagulation, acute respiratory distress syndrome and acute
pancreatitis. DZUVEO and Zalviso are both approved products in
Europe.
For additional information about AcelRx, please visit
www.acelrx.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/acelrx-to-host-fourth-quarter-and-full-year-2021-financial-results-call-and-webcast-on-march-10-2022-301495389.html
SOURCE AcelRx Pharmaceuticals, Inc.